2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences
XTalks
DECEMBER 24, 2020
As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes. CRISPR Therapeutics.
111 
Let's personalize your content